title: Chronic migraine plus medication overuse headache: two entities or not?
abstract: Chronic migraine (CM) represents migraine natural evolution from its episodic form. It is realized through a chronicization phase that may require months or years and varies from patient to patient. The transition to more frequent attacks pattern is influenced by lifestyle, life events, comorbid conditions and personal genetic terrain, and it often leads to acute drugs overuse. Medication overuse headache (MOH) may complicate every type of headache and all the drugs employed for headache treatment can cause MOH. The first step in the management of CM complicated by medication overuse must be the withdrawal of the overused drugs and a detoxification treatment. The goal is not only to detoxify the patient and stop the chronic headache but also to improve responsiveness to acute or prophylactic drugs. Different methods have been suggested: gradual or abrupt withdrawal; home treatment, hospitalization, or a day-hospital setting; re-prophylaxes performed immediately or at the end of the wash-out period. Up to now, only topiramate and local injection of onabotulinumtoxinA have shown efficacy as therapeutic agents for re-prophylaxis after detoxification in patients with CM with and without medication overuse. Although the two treatments showed similar efficacy, onabotulinumtoxinA is associated with a better adverse events profile. Recently, the Phase III Research Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical program proved that patients with CM, even those with MOH, are the ones most likely to benefit from onabotulinumtoxinA treatment. Furthermore, it provided an injection paradigm that can be used as a guide for a correct administration of onabotulinumtoxinA.
authors.affiliation: Department of Medical and Molecular Sciences, Sapienza University, Rome, Italy. andrea.negro@uniroma1.it
authors.forename: Andrea
authors.initials: A
authors.lastname: Negro
authors.forename: Paolo
authors.initials: P
authors.lastname: Martelletti
mesh_terms: D000700:Analgesics / Q000008:administration & dosage / Q000009:adverse effects*; D003937:Diagnosis, Differential; D020773:Headache Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D051271:Headache Disorders, Secondary / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D006801:Humans; D020326:Migraine without Aura / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D028761:Withholding Treatment / Q000592:standards
chemical_list: D000700:Analgesics